1. Scrip
  2. >>R&D

Abbott’s Cloherty On Viral Surveillance And Evolving Viruses

 
• By Anju Ghangurde

Gavin Cloherty, Abbott’s head of infectious disease research, tells Scrip how the company’s global viral surveillance program helps it stay ahead of HIV and hepatitis evolution, outlines efforts at a partnership in India on viral diversity to help improve diagnostic accuracy and shares new findings from the company’s virus discovery program.

Cloherty_Gavin
Dr Gavin Cloherty, Head of Infectious Disease Research, Abbott • Source: Abbott

India joined Abbott Laboratories Inc.’s global viral surveillance efforts last year and Gavin Cloherty, the US company’s head of infectious disease research, highlighted how things are shaping in its alliance in the area with YRG CARE, a leading institution for HIV/AIDS research in India.

YRG Care was founded by the late Dr Suniti Solomon, who documented the first cases of HIV infection in the country and is

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.